OncoSec Medical Inc (ONCSQ)

[InTheTrenches]

Triple Negative Breast Cancer treatment overview (Journal of Oncology Practice):

http://ascopubs.org/doi/full/10.1200/JOP.2017.023333

"Breast cancer is the most frequent tumor worldwide, and approximately 255,000 women will be diagnosed with breast cancer in the United States in 2017. Approximately 10% to 20% of these patients will be diagnosed with [triple-negative breast cancers or TNBC]"

"...[TNBCs] present with a varied natural history but are collectively associated with poor prognosis with high risk of relapse and short progression-free survival (PFS) and overall survival (OS). As many as 50% of patients diagnosed with early-stage TNBC (stages I to III) experience disease recurrence, and 37% die in the first 5 years after surgery."

"...indicating the pressing need for drug development for treating [TNBC]."

"Finally, immune therapy has gained unprecedented momentum with checkpoint inhibitors that show significant efficacy and favorable toxicity profile for the treatment of solid tumors. [TNBC] is thought to have a high frequency of genomic alteration and neoantigen formation. Pembrolizumab [Keytruda], however, which is a monoclonal anti-programmed cell death protein 1 (PD-1) antibody was tested in a phase Ib trial of 32 patients with programmed death ligand 1 (PD-L1)–positive [TNBC] and showed a modest response rate of 18.5%. Investigational strategies, including the combination of different checkpoint inhibitors and the development of antibody-drug conjugates, are ongoing."